<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05792410</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-A1811-206</org_study_id>
    <nct_id>NCT05792410</nct_id>
  </id_info>
  <brief_title>A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.</brief_title>
  <official_title>An Open, Multicenter Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Dalpiciclib, Fulvestrant, Bevacizumab or Letrozole/Anastrozole in Patients With HER2 Low Advanced or Metastatic Breast Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the safety, tolerability, PK and preliminary anti-tumour activity&#xD;
      of SHR-A1811 combined with other therapies in patients with HER2 low advanced or metastatic&#xD;
      breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2023</start_date>
  <completion_date type="Anticipated">February 27, 2025</completion_date>
  <primary_completion_date type="Anticipated">February 27, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>An open, multicenter, dose-finding and dose expansion investigational Phase IB/II clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DLT(Phase I (dose-finding phase) main study endpoint)</measure>
    <time_frame>At the end of cycle 1(each cycle is 28 days for SHR-A1811+ fulvestrant; each cycle is 21 days for SHR-A1811+other therapies.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AE(Phase I (dose-finding phase) main study endpoint)</measure>
    <time_frame>Up to follow-up period, approximately 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of serious adverse events (SAE)(Phase I (dose-finding phase) main study endpoint)</measure>
    <time_frame>Up to follow-up period, approximately 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate(The main end points of the second stage (efficacy expansion stage))</measure>
    <time_frame>Until progression, assessed up to approximately 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>SHR-A1811 sparse PK concentrations in serum</measure>
    <time_frame>While on study drug up to study completion, approximately 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dalpiciclib sparse PK concentrations in plasm</measure>
    <time_frame>While on study drug up to study completion, approximately 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibodies (ADA) to SHR-A1811 over time</measure>
    <time_frame>Up to follow-up period, approximately 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of neutralizing antibody (NAb) to SHR-A1811 over time</measure>
    <time_frame>Up to follow-up period, approximately 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>Until progression or death, assessed up to approximately 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Until progression or death, assessed up to approximately 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>HER2 Low Advanced or Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>SHR-A1811 combined with Dalpiciclib Isethionate Tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR-A1811 combined with Fulvestrant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR-A1811 combined with Bevacizumab injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-A1811 &amp; Dalpiciclib Isethionate Tablets</intervention_name>
    <description>SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Dalpiciclib Isethionate Tablets：Tablet, 25mg / tablet, 50mg / tablet, 125mg / tablet, 150mg / tablet, oral</description>
    <arm_group_label>SHR-A1811 combined with Dalpiciclib Isethionate Tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-A1811 &amp; Fulvestrant</intervention_name>
    <description>SHR-A1811：Lyophilized powder injection, 100mg / bottle, intramuscular Fulvestrant：Injection, 5 ml: 0.25g/bottle, intramuscular</description>
    <arm_group_label>SHR-A1811 combined with Fulvestrant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-A1811 &amp; Bevacizumab injection</intervention_name>
    <description>SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Bevacizumab injection: injection, 100mg / bottle, intravenous drip</description>
    <arm_group_label>SHR-A1811 combined with Bevacizumab injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability to give informed consent, signed and dated IRB/EC approved informed consent,&#xD;
             willing and able to comply with treatment planning visits, tests and other procedural&#xD;
             requirements&#xD;
&#xD;
          2. When signing the informed consent, the age is 18-75 years old (including both ends),&#xD;
             female patients who have pathologically documented HER2 low breast cancer&#xD;
&#xD;
          3. ECOG Performance Status of 0 or 1&#xD;
&#xD;
          4. Patient must have adequate tumor sample for biomarker assessment&#xD;
&#xD;
          5. At least one measurable lesion&#xD;
&#xD;
          6. Adequate organ function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. There are untreated or active central nervous system (CNS) tumor metastases&#xD;
&#xD;
          2. There was a third space effusion that could not be controlled by drainage (such as a&#xD;
             large number of ascites, pleural effusion and pericardial effusion)&#xD;
&#xD;
          3. Major surgery within 4 weeks prior to enrollment&#xD;
&#xD;
          4. Has multiple primary malignancies within 5 years, excluding cured basal cell carcinoma&#xD;
             of skin, cervical carcinoma in situ, papillary thyroid carcinoma, etc&#xD;
&#xD;
          5. Has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out at&#xD;
             screening&#xD;
&#xD;
          6. Uncontrolled intercurrent illness&#xD;
&#xD;
          7. Uncontrolled or significant cardiovascular disease&#xD;
&#xD;
          8. Has known human immunodeficiency virus (HIV) infection, or active hepatitis B or C&#xD;
             infection.&#xD;
&#xD;
          9. According to NCI-CTCAE v5.0 classification, those who have not recovered to grade Ⅰ&#xD;
             toxicity caused by previous anti-tumour treatment&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shuchao Wu</last_name>
    <phone>+0518-81220121</phone>
    <email>shuchao.wu@hengrui.com.cn</email>
  </overall_contact>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>February 17, 2023</study_first_submitted>
  <study_first_submitted_qc>March 19, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2023</study_first_posted>
  <last_update_submitted>March 19, 2023</last_update_submitted>
  <last_update_submitted_qc>March 19, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

